Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment
Authors:
Open Access
- 15 January 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1530887
Abstract
Cell therapy is an emerging strategy for precision treatment of scleroderma. This review systematically summarizes the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies in scleroderma and discusses the challenges and future directions for development. MSCs possess multiple functions, including immunomodulation, anti-fibrosis, and promotion of vascular regeneration, all of which can improve multiple pathological processes associated with scleroderma. Studies have demonstrated that MSCs can alleviate skin fibrosis by inhibiting CCL2 production and reducing the recruitment of pathological macrophages; their paracrine effects can exert extensive regulatory functions. CAR-T cell therapy ca specifically target and eliminate autoreactive immune cells, exhibiting enhanced specificity and personalized potential. Different cell therapies may have complementary and synergistic effects in treating scleroderma, such as MSCs exerting their effects through paracrine mechanisms while CAR-T cells specifically eliminate pathological cells. Furthermore, cell-free therapies derived from MSCs, such as extracellular vesicles or exosomes, may help circumvent the limitations of MSC therapy. Although cell therapy has opened new avenues for the precision treatment of scleroderma, it still faces numerous challenges. In the future, it is essential to strengthen integration of basic and clinical research, establish standardized protocols for cell preparation and quality control, develop personalized treatment plans, and rationally combine cell therapy with existing treatment methods to maximize its advantages and improve patient prognosis and quality of life.Keywords
This publication has 64 references indexed in Scilit:
- CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?Zeitschrift für Rheumatologie, 2024
- Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up studyClinical Rheumatology, 2024
- Is There a Place for Chimeric Antigen Receptor–T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?Arthritis & Rheumatology, 2021
- Stem Cell Therapy as a Treatment for Autoimmune Disease—Updates in Lupus, Scleroderma, and Multiple SclerosisCurrent Allergy and Asthma Reports, 2021
- Mesenchymale Stammzelltherapie bei AutoimmunerkrankungenZeitschrift für Rheumatologie, 2020
- A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic DiseasesRheumatology and Therapy, 2018
- Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic SclerosisClinical Reviews in Allergy & Immunology, 2016
- Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl‐Induced Systemic SclerosisArthritis & Rheumatology, 2016
- Exosomes Derived from Mesenchymal Stromal Cells Promote Axonal Growth of Cortical NeuronsMolecular Neurobiology, 2016
- Use of Mesenchymal Stem Cells (MSC) in Chronic Inflammatory Fistulizing and Fibrotic Diseases: a Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2013